Table 2.
Characteristics of five-year survivors without disease recurrence
| Age/gender | CA19-9 (U/mL) | Tumor location | Tumor size (mm) | UICC stage | TNM-N | Number of lymph node metastasis | Surgery | R | Outcome (month) | Recurrence |
|---|---|---|---|---|---|---|---|---|---|---|
| 71/F | 2 | Pb | 16 | IA | 0 | 0 | DP | 0 | 68/A | None |
| 76/F | 65 | Ph | 30 | IIB | 1 | 2 | PD | 0 | 69/D | None |
| 72/M | 597 | Pt | 40 | IIB | 1 | 2 | DP | 1 | 73/D | Dissemination |
| 57/M | 611 | Ph | 42 | IIB | 0 | 0 | PD with PV | 0 | 74/A | None |
| 73/F | 3221 | Pbt | 32 | IIB | 1 | 2 | DP | 0 | 78/A | None |
| 76/M | 21 | Ph | 20 | IIA | 0 | 0 | PD | 0 | 79/D | None |
| 62/M | 103 | Ph | 40 | IIB | 1 | 2 | PD | 0 | 85/D | Lymph node |
| 61/M | 29 | Ph | 12 | IIA | 0 | 0 | PD | 1 | 86/A | None |
| 46/M | 31 | Ph | 40 | IIA | 0 | 0 | PD | 0 | 89/D | Liver/local |
| 68/F | 2381 | Ph | 55 | IIA | 0 | 0 | PD | 0 | 92/A | None |
| 73/M | 39 | Pb | 38 | IIB | 1 | 1 | DP | 0 | 100/A | None |
| 60/F | 34 | Ph | 50 | IIB | 1 | 2 | PD | 0 | 108/A | None |
| 70/M | 29 | Ph | 32 | IB | 0 | 0 | PD | 0 | 111/A | None |
| 57/M | 20 | Ph | 30 | IIB | 1 | 2 | PD with PV | 1 | 122/D | Lung/skin |
| 56/M | 4.1 | Ph | 20 | IIA | 0 | 0 | PD | 0 | 129/D | None |
| 57/M | 30 | Pb | 30 | IB | 0 | 0 | DP | 0 | 144/A | None |
| 57/M | 7 | Pb | 35 | IIA | 0 | 0 | DP | 0 | 145/A | None |
| 70/M | 2 | Ph | 15 | IIB | 1 | 1 | PD | 1 | 170/A | None |
A, alive; D, dead; DP, distal pancreatectomy; Pb, body of the pancreas; Pbt, body and tail of the pancreas; PD, pancreaticoduodenectomy; Ph, head of the pancreas; Pt, tail of the pancreas; PV, portal vein resection; R, resection status.